Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model |  MarketScreener

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model | MarketScreener

Myriad’s MyRisk™ hereditary cancer test with RiskScore® provides personalized breast cancer risk assessment for women of all backgrounds

SALT LAKE CITY, 08 Dec. 10, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a simple standard of care risk assessment. The data was shared during a spotlight discussion at the 2022 San Antonio Breast Cancer Symposium.

In collaboration with leading researchers, Myriad Genetics studied the results of more than 130,000 women who received RiskScore results. By analyzing data indicating whether women developed breast cancer after their initial test result, the study demonstrated that RiskScore was more accurate at stratifying women at high or low risk of developing breast cancer than a standard risk assessment method. Based on these findings, the clinical use of RiskScore may lead to improved breast cancer prevention and screening strategies.

“This study helps validate the performance of a polygenic risk score in a real-world setting and advances our approach to breast cancer risk assessment,” said Allison Kurian, MD, M.Sc., University of Stanford and co-author of the study study.

RiskScore is the first breast cancer risk prediction model that combines Tyrer-Cuzick with a validated polygenic risk score (PRS) for women of all backgrounds. It provides a five-year and lifetime breast cancer risk assessment for women who qualify for the MyRisk hereditary cancer screening test.

“Personalised breast cancer risk assessment depends on known traditional risk factors, specific germline mutations, and genome-wide PRS. This longitudinal patient outcome study highlights RiskScore as a valuable tool precision medicine to predict breast cancer risk,” said Thomas Slavin, MD, Chief Medical Officer of Myriad Genetics. “With RiskScore, more women will benefit from knowing their genomic risk of developing breast cancer and work with their doctors on how best to manage this risk.”

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to promoting health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing a disease or its progression and guide treatment decisions in medical specialties where genetic information can significantly improve patient care and reduce healthcare costs. . Fast Company named Myriad among The most innovative companies in the world for 2022. For more information, visit

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore , Prolaris, GeneSight and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of using RiskScore and that with RiskScore more women will benefit from knowing their genomically informed risk of developing breast cancer and working with their doctors on how best to manage that risk. These “forward-looking statements” are based on management’s expectations regarding future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause results, conditions and actual events differ materially and adversely from those anticipated. These factors include the risks described in the company’s filings with the United States Securities and Exchange Commission, including the company’s annual report on Form 10-K filed on February 25, 2022, as well as any updates of these risk factors filed from time to time in the company’s quarterly reports on Form 10-Q or current reports on Form 8-K.

Media Contact:
Megan Manzari
(385) 318-3718
Investor contacts:
Matt Scalo
(801) 584-3532

#Myriad #Genetics #Patient #Outcome #Study #Shows #RiskScore #Leads #Accurate #Breast #Cancer #Risk #Prediction #Standard #Risk #Model #MarketScreener

Leave a Comment

Your email address will not be published. Required fields are marked *